Who was studied, and how
Six numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 2 other studies
1,363people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
metformin
control
Lowered glucose−1.78
Lowered CRP−0.60
Lowered insulin resistance−0.45
randomisedthe abstract, start to end
… significant reduction in insulin (WMD: - 0.99 U/ml, 95% CI - 1.66, - 0.33), glucose (WMD: - 1.78 ml/dl, 95% CI - 2.96, - 0.60), CRP (WMD: - 0.60 mg/l, 95% CI - 0.88, - 0.33), HOMA-IR (WMD: - 0.45, 95% CI - 0.77, - 0.11), leptin (WMD: - 2.44 ng/ml, 95% CI - 3.28, - 1.61), BMI (WMD: - 0.55 kg/m CONCLUSIONS: Breast cancer …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Insulinmetformin vs control
−0.99−1.66 to −0.33
Glucosemetformin vs control
−1.78−2.96 to −0.60
CRPmetformin vs control
−0.60−0.88 to −0.33
HOMA-IRmetformin vs control
−0.45−0.77 to −0.11
Leptinmetformin vs control
−2.44−3.28 to −1.61
BMImetformin vs control
−0.55
MetforminGlycemic controlBody weight & compositionInflammation & biomarkers
Metformin × inflammation & biomarkershelps?one trial
unlikelylikely
0.50not counted
Metformin × glycemic controlhelps?replicated
unlikelylikely
0.84not counted
← favours comparatorfavours treatment →
1 / 7